4 Stages of Prostate Cancer: Stage-by-Stage Outlook and Treatment

The 4 stages of prostate cancer describe how far a tumor has spread, and each stage carries a different outlook and treatment path. Stage I is confined to the prostate with a low Gleason score and a 5-year relative survival near 100 percent. Stage II is still confined but higher risk. Stage III has broken through the prostate capsule or reached the seminal vesicles. Stage IV has spread to lymph nodes or distant organs such as bone, where 5-year relative survival is about 37 percent. Staging drives every decision that follows.

How Prostate Cancer Staging Actually Works

Prostate cancer staging is not one test. It is a synthesis of three independent data streams: the tumor's physical extent (T), lymph node involvement (N), and distant spread (M). These feed the TNM system, which the American Joint Committee on Cancer revised in its 8th edition, effective 2018. That revision folded the prostate-specific antigen (PSA) level and the Gleason grade group into the stage itself, so a man with identical imaging findings can land in a different stage based on his pathology.

The Gleason score is the engine underneath. A pathologist grades the two most common cell patterns on a biopsy from 1 to 5 each and adds them. A score of 6 is the lowest that counts as cancer. Grades 7 to 10 are grouped into Grade Groups 1 through 5, a scale introduced because a Gleason 7 split into 3+4 versus 4+3 behaves very differently. Grade Group 1 (Gleason 6 or less) is the least aggressive; Grade Group 5 (Gleason 9 to 10) is the most.

In plain terms: staging answers two questions at once, how abnormal the cells look and how far they have traveled.

The 4 Stages of Prostate Cancer, Side by Side

The table below reconciles the defining features of each stage. Note that the PSA thresholds and Gleason bands are the AJCC 8th edition cutoffs; a man can meet the imaging criteria for one stage but be moved by his lab values.

The survival figures come from the American Cancer Society's surveillance data, which pools cases diagnosed between 2012 and 2018. The gap between Stage III at roughly 95 percent and Stage IV at 37 percent is the single most important number in this article. It is why early detection and accurate staging carry so much weight.

Stage I and Stage II: Confined Disease and Active Surveillance

Stage I and Stage II share one defining fact: the cancer has not left the prostate capsule. What separates them is risk. Stage I is low risk, typically PSA under 10 and Grade Group 1. Stage II adds intermediate risk through a higher PSA (10 to 20) or a higher grade (Grade Group 2 or 3).

This distinction matters because it changes whether treatment is even recommended. For Stage I, active surveillance is a legitimate first-line option, not a delay tactic. Under active surveillance, a man gets PSA testing every 3 to 6 months, a repeat biopsy at roughly 1 year, and periodic MRI. Roughly 30 to 50 percent of men on active surveillance eventually move to treatment, usually because the grade rises on a repeat biopsy. The rest avoid surgery or radiation entirely.

Stage II often tips toward definitive treatment. Options include radical prostatectomy, external beam radiation, or brachytherapy. Five-year survival in both stages sits near 100 percent, and 10-year disease-specific survival for low-risk disease exceeds 98 percent. The counterintuitive part: for many Stage I men, the treatment decision is about quality of life, not survival, because the cancer is unlikely to kill them within their natural lifespan.

Stage III: Local Spread and the Case for Combined Therapy

Stage III means the tumor has pushed through the prostate capsule (T3) or invaded the seminal vesicles or nearby structures (T4), but has not reached lymph nodes or distant organs. This is locally advanced disease. It is the stage where single-modality treatment starts to underperform.

The landmark evidence here is the addition of androgen deprivation therapy (ADT) to radiation. Per long-term trial data published by Bolla and colleagues, adding ADT to external beam radiation improved overall survival in locally advanced disease compared with radiation alone. Modern practice often layers a second drug, such as abiraterone or a newer androgen receptor blocker, on top of ADT plus radiation for higher-risk Stage III cases. Surgery is sometimes performed but usually as part of a multimodal plan.

Stage III five-year relative survival is about 95 percent, but that figure hides real variability. A T3a tumor with Grade Group 2 behaves far better than a T4 tumor with Grade Group 5. This is the stage where the Gleason grade, not the T number, most strongly predicts outcome.

Stage IV: Metastatic Disease and the Shift in Treatment

Stage IV splits into two very different situations. Stage IVA means the cancer has reached regional lymph nodes only (N1, M0). Stage IVB means distant metastasis, most often to bone (M1). The distinction is not cosmetic: IVA still has a meaningful chance of long-term control, while IVB is generally incurable but increasingly treatable.

Bone is the dominant metastatic site, involved in roughly 90 percent of metastatic prostate cancer cases. This is not random. Prostate cancer cells thrive in the bone marrow environment, where they interact with bone-forming and bone-resorbing cells to create the characteristic sclerotic (dense) lesions seen on imaging. That mechanism explains why bone pain and fracture risk are common complications, and why bone-protective drugs such as denosumab or zoledronic acid are used alongside cancer therapy.

Modern Stage IVB treatment has changed the survival curve. Adding drugs like abiraterone, enzalutamide, or docetaxel to standard ADT extends median overall survival into the range of 4 to 5 years in many patients, well beyond the historical 2 to 3 years. The 37 percent five-year relative survival figure reflects a mix of patients diagnosed before these combinations were standard. Recent cohorts are doing better, though the improvement is a trend, not yet a settled new benchmark.

A Timeline of What Staging and Treatment Look Like

The table below maps the typical sequence of events once a man enters the staging pathway. Timelines vary by health system and individual risk.

The PSMA PET scan deserves a note. Prostate-specific membrane antigen PET imaging, approved by the FDA in 2020 and expanded since, detects spread far more sensitively than older bone and CT scans. It has quietly upstaged a meaningful fraction of men who would previously have been called Stage III, moving them to Stage IV before treatment even starts.

Common Misconceptions About Prostate Cancer Stages

Several beliefs about staging are wrong in ways that affect decisions.

The most persistent: a higher stage always means a worse outcome. For Stage III, the grade often matters more than the T number, and some Stage III men outlive some Stage II men with high-grade disease. Stage is a snapshot, not a verdict.

A second misconception: survival percentages describe an individual. A 37 percent five-year survival for Stage IVB is a population average across ages, treatments, and tumor biology. A healthy 60-year-old on modern combination therapy is not the average patient in that number.

A third: staging happens once. In reality, restaging occurs after recurrence. A man treated for Stage II who later develops a rising PSA and a positive PSMA scan has effectively moved to a metastatic stage, and the treatment plan changes accordingly.

The edge case worth flagging: some men have a normal PSA but aggressive Grade Group 4 or 5 disease. PSA is not a reliable stage proxy in every case, which is why biopsy grade and imaging must be read together.

What to Actually Do After a Stage Is Assigned

The stage is a starting point, not a final answer. Concrete next steps:

• Ask for the full pathology report, including the Gleason score broken into its two components (for example, 3+4 versus 4+3), not just the total.
• Request a PSMA PET scan if metastasis is suspected; it changes staging in a meaningful share of cases.
• For Stage I, discuss active surveillance explicitly before agreeing to surgery or radiation.
• For Stage III or IV, ask whether a multidisciplinary tumor board reviewed the case and whether combination therapy is appropriate.
• Get a baseline bone health assessment if ADT is planned, since ADT accelerates bone loss.
• Track PSA on a fixed schedule and keep the trend, not single values, in front of you.

Red-flag symptoms that warrant urgent attention at any stage:

• New, persistent bone pain, especially in the back or hips.
• Difficulty urinating or blood in the urine.
• Unexplained weight loss or fatigue.
• Leg weakness or numbness, which can signal spinal cord compression from metastasis.
• A rapidly rising PSA after treatment.

Limits of Staging and Survival Numbers

Staging is a powerful tool with real limits. The survival percentages are retrospective population averages, not predictions. They lag behind current treatment because they describe patients diagnosed years ago. They also collapse enormous biological variation into one number.

The Gleason grading system itself has a reproducibility problem. Pathologists disagree on grade in a nontrivial fraction of borderline cases, and a Gleason 7 read by one pathologist may be read as 6 or 8 by another. Second-opinion pathology review is common for this reason.

Finally, the 4-stage framework is a map, not the territory. Two men with the same stage can have very different tumors at the molecular level, and research into genomic classifiers is beginning to stratify risk beyond stage and grade. That work is promising but not yet standard. For now, the 4 stages of prostate cancer remain the shared language clinicians use to plan treatment, and understanding what each stage actually means is the first step toward a decision that fits the individual.